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A B S T R A C T
Malignant melanoma genesis is a very complex process that involves a sequence of pathogenetic cellular events. Muta-
tion of various genes and numerous other cellular mechanisms play an important role in the course of malignant me-
lanocyte alteration and their malignant transformation from naevi into melanoma. Apoptosis is an active, genetically
controlled process of programmed cell death, which leads to cell destruction and cell death without involvement of sur-
rounding cells or inflammatory response. In this process, disrupted mechanisms of cell regulation and apoptosis take
place in malignant melanoma cells, thus leading to their uncontrolled proliferation and melanocyte growth. Apoptosis is
a process that involves two major pathways, the intrinsic and extrinsic apoptotic pathway, which interlace at certain
points and ultimately result in apoptosis. It can be said that molecular events regulating cell survival, nomal growth ar-
rest, apoptosis and cell differentiation, contribute to the overall pathogenesis of malignant cell growth. It is presumed
that in the future, understanding of molecular aberrations and cellular processes, such as cell signaling, cell cycle regu-
lation and cell apoptosis, will be essential for better patient monitoring and rational design of effective treatment.
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Introduction
It is well-known that the development of all skin car-
cinomas, as well as malignant melanoma, is a complex
multiphase process. Regarding many unknown terms in
molecular pathogenic events, those carcinogenesis mech-
anisms are still reviewed.
Cell division as well as cell death play the main role in
the precise control of cell count and tissue size. Apoptosis
is an active, genetically controlled process of program-
med cell death which leads to cell destruction, and during
which there is no surrounding cells or inflammatory re-
sponse involvement1,2. It is important to notice the im-
portance of molecular events that regulate the apoptosis,
cell survival, delay of cell growth and cell differentiation
regarding carcinogenesis process3–5. It is well-known that
the malignant tumor cells have defect mechanisms of
regulation and apoptosis, whereupon cell proliferation is
uncontrolled. Meanwhile, proliferation balance and apo-
ptosis can implicate the risk of malignant transformation
and consequently development of malignant melanoma6,7.
Despite that, it is noticed that acting on cell apoptosis
and renewal of disrupted cell apoptotic and regulating
processes could be a promissing way of skin carcinoma
treatment, including malignant melanoma8.
The apoptosis itself as a cell death process includes
number of pathogenetic events. That process includes
two apoptotic pathways, intrinsic and extrinsic pathway,
which converge in many points, and finally lead to cell
death9. In that complex process numerous enzymes are
included such as caspases. Caspases are proteases with
cysteine tail, which cleave proteins behind the aspartic
acid end, leading to termination of apoptosis. Twelve
caspases have so far been identified, among which there
are initiator and effective caspases. Initiator caspases
(e.g. 8 and 9) cleave inactive pro-forms of effector cas-
pases, thereby activating them, while effector caspases
(e.g. 3, 6 and 7) subsequently cleave other cell proteins
and trigger apoptotic cell death.
Development of malignant melanoma is very complex
process. It is known that melanocytes, except in benign
and malignant neoplasms, reside within the basal layer
of the epidermis, while its dendrites come into contact
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with keratinocytes as far as the mid stratum spinosum10.
It is presumed that keratinocytes participate in cell adhe-
sion and control the growth of melanocytes and expres-
sion of surface receptors. Melanoma arises from multipli-
cation of transformed melanocytes in the epidermis,
avoiding keratinocyte control. Multiplication of melano-
cytes can lead to cell hyperplasia, dysplasia, malignant
melanoma, invasion and metastases11. Melanogenesis
encompasses numerous molecular events, where genetic
mutations play a great role8. Mutations of various genes
are important in that process, for example, NRAS or
BRAF gene and CDKN2A or PTEN gene.
The role of FasL molecule, expressed on the cell sur-
face of melanocytes, which is involved in avoiding the
imunologic cells action, is also important in melano-
genesis. It is noticed that once malignant transformation
of melanocytes takes place, they express FasL, which al-
lows melanoma to avoid the immune response. It is also
well-known that UV radiation decreases FasL expression
on melanocytes. As a result, cell surface interactions be-
tween FasL and Fas on adjacent cells are not possible,
apoptosis can be inhibited, resulting in multiplication of
transformed cells and carcinogenesis8. In the process of
carcinogenesis there are number of cell transformation
stages: initiation/induction, promotion, premalignant pro-
gression and malignant conversion6. It is shown that the
onset (initiation) of carcinogenesis is a result of genetic
impairment caused by exogenous agent (for example UV
radiation) that changes the pathway of cell proliferative
control and/or differentiation. Afterwards, expansion of
driven cell population or clone arises (promotion), and it
is believed that it is a product of epigenetic effects. Pro-
gression and conversion are marked by cells with high
level of genetic instability, chromosomal abnormalities, ex-
pression of surface molecules and oncogenic activities12.
Although sun exposure probably plays a leading or
supporting role in melanogenesis, the aetiology of mela-
noma is probably variable and multifactorial3. It is signif-
icant that molecular events which regulate cell survival,
delay of cell growth, apoptosis and cell differentiation
have an important role in the process of malignant cell
growth4,13.
Therefore, it is attempted to act on that pathogenic
mechanisms, as potential therapeutic aims.
Genetic and Other Factors in Pathogenesis
of Malignant Melanoma
The important factors in melanogenesis are genetic
mutations, especially CDKN2A, PTEN, NRAS or BRAF
gene mutations8. Mutations in NRAS or BRAF gene can
cause abnormal constitutive activation serine-threonine
kinases in ERK-MAPK pathway of melanoma cells
growth stimulation14. It has been shown by in vitro anal-
ysis that melanoma cells growth is induced by activation
of NRAS and BRAF genes15. Mutations in CDKN2A or
PTEN genes are another step in melanogenesis. Muta-
tions in CDKN2A gene have been implicated in 25–40%
of hereditary melanomas, while mutations in PTEN gene
have been found in 25–50% of nonhereditary melano-
mas16. It is stated that especially the mutations in
CDKN2A gene increase probability of development ma-
lignant melanoma. CDKN2A encodes two protein prod-
ucts, p16 and p14 ARF (alternate reading frame), which
are both negative regulators of cell cycle progression.
The net effect of a CDKN2A mutation with loss of
p14ARF function is decreased p53 function with en-
chanced growth of altered cells. Therefore, mutation in
CDKN2A gene prevents recruitment of ARF. Immortal-
ity of cells in lack of ARF or p53 has been often shown in
several studies8,16.
Common mutations that effect CDKN2A locus in mel-
anomas typically target p16INK4A, suggesting a significant
role of this protein in melanocyte cell cycle control main-
tenance. It seems that this gene is destroyed in about
50% of melanomas and inactivated by point mutations in
about 9% of tumors17.
Conduction of genetic studies is significant because of
the effort of implementing gene therapy that is still stud-
ied. There are efforts to turn down various/these genes
by impeding with RNA, using specific small interfering
RNA (siRNA) or short hairpin RNA (shRNA). Such in-
vestigations have shown functional success in tissue cul-
tures as well as tumor tissues, and in mice models.
Therefore, siRNA could represent a promissing approach
to skin cancer treatment in the early stage8.
It is impotant to emphasize cell cycle expression and
apoptotic regulating proteins and telomerases in me-
lanocytic lesions18. Studies have shown that the main
role in apoptosis initiation and cell cycle control pertains
to p53 protein which is known tumor supressor3,18–20.
Dysplastic nevi show significantly higher expression of
p53 protein in contrast to malignant melanomas, which
suggests the importance to discover other factors in mel-
anoma progression18. However, it has also been reported
that p53 gene is not often mutated in melanomas1,2. Nev-
ertheless, most genotoxic substances participate in apo-
ptosis induction through p53, so it is assumed that mela-
noma cells are sensitive to DNA damage3,18.
Capacity of cell proliferation (therefore melanocytes),
cancerogenesis and cell immortality are controlled by the
enzyme telomerase. It has be shown that the activation
of telomerase is significant in pathogenesis of numerous
malignant tumors in humans18.Telomerase is a DNA
polymerase involved in the formation of telomeres and
the maintenance of telomere sequences during replica-
tion. The role of telomeres is to protect the chromosomes
from degradation and aberrant recombinations during
replication in order to postpone apoptosis of the cell18. In-
creased activity of telomerases is related to progression
of dysplastic nevus into malignant melanoma. This fact
represents an evidence that telomerase has an active
anti-apoptotic role.
Several studies have shown that melanogenesis is as-
sociated with decrease of other anti-apoptotic proteins
such as bcl-x and increase of bcl-2 protein expression.
However, several results indicate that in all tissues of
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mealnocytic origin there is a decrease of anti-apoptotic
proteins or detectable level of bcl-221,22.
Development, differentiation and maintenance of me-
lanocytes is regulated by MITF factor (microphtalmia-
-associated transcription factor). In melanoma with poor
prognosis MITF amplification has been often perceived
with poor response on chemotherapy. In vitro analyses
have prooven that excessive expression of MITF changes
melanocytes, which indicates that MITF is an oncogen.
According to that MITF could be potential therapeutic
target8.
In later stage of disease dissemination, invasion and
metastases are result of changes in cell adhesion mole-
cules, including cadherines and integrines8. Cadherines
are important adhesion cell molecules, ensuring commu-
nication with actin cytoskeleton and inducing signal by
b-catenine that is linked to WNT (wingless-type mam-
mary tumor integration-site family) pathway. Changes in
cadherine expression affect melanoma cell interaction
with keratinocytes and alternate b-catenine signaling.
On the other hand, integrines mediate cell contact with
components of extracellular matrix, for example cami-
nin, collagen and fibronectin. Melanoma growth is asso-
ciated with expression of a5b3 integrines increasing the
expression of antiapoptotic bcl-223.
Recently a comprehensive review of several possible
pathways of progression of melanocytes into melanoma
has been published, but the question remains why im-
mune system can’t efficiently inhibit carcinogenesis24.
This question remains unsolved despite the fact that sev-
eral tumor antigens have been discovered in human mel-
anomas that could initiate host immune response to mel-
anoma, such as antigens coded by carcinoma development
genes (for example, various MAGE genes), or coded by
differentiation genes (Melan-a/Mart-1, gp 100/pMel,
17TRP-1, TRP-2 and others), or antigens which are a re-
sult of point mutations (for example, CDK4)25.
It has been reported that patients with melanoma
usually develop T-cell response to melanoma, but T-cells
quickly become uneffective. This is generally a conse-
quence of local immunosuppression at the sight of tumor,
for example development of T-cell anergy and gaining tu-
mor resistance to apoptosis. Local immunosuppression
also may be accountable for failure of vaccination by tu-
mor-specific antigens in most of patients25.
Future of Molecular Knowledge and
Therapeutical Effects in Malignant
Melanoma
In patients with malignant melanoma it is important
to perform an operative procedure as soon as possible to
prevent potential spreading of the tumor. Other forms of
treatment in advanced phase of disease include chemo-
therapy, irradiation, interferon therapy and other. Cellu-
lar apoptosis is the main mechanism by which mentioned
methods perform their anticarcinogeneous role, includ-
ing cytotoxic chemotherapy, irradiation, hormonal ther-
apy and new biological medications26. Ground on which
carcinomatous cells, incuding melanomas, are resistant
to many of these methods of treatment is survival signal-
ing, which bypasses apoptotic cell death, and represents
a therapeutic target27–29.
It is important to understand of the complexity of
clinical variety of melanoma and emphasize the idea that
melanoma is, like other tumors, not just a solitary dis-
ease, but a heterogeneous group of disorders that develop
from complex molecular changes. Knowledge of the mole-
cular aberrations and important cellular processes, such
as network of cell signaling, regulation of cell cycle and
cell death, is important for better diagnosing, more accu-
rate prognosis evaluation and rational plan of efficient
treatment9.
Despite various possibilities of treatment, there is a
need for more simple and effective modes of treatment in
the future, including biological response modificators
and gene therapy8. In this manner, cell apoptotic path-
ways and apoptotic death could represent a crucial physi-
ological mechanism of tissue homeostasis and growth
regulation. Such new knowledge should be used in devel-
opment of new medications based on apoptosis, with goal
of cell protection, especially in cases of weakened cell
mortality, like in malignant tumors3.
Although there are already many various therapeutic
possibilities in malignant melanoma, success is still not
optimal, especially in the treatment of metastases and
advanced stages of tumor development. Discovery of sev-
eral mutations of genes in patients with familiar mela-
noma (for example PTEN), and several genes which have
not been previously implicated in melanogenesis, is im-
portant in developing new therapeutic strategies8,23. There
are many expectations in the future for method of turn-
ing down the genes by RNA interfering, and that could
be the new and promissing approach. Such methods of in
vivo siRNA or shRNA delivery should still be improved
and should find a precise target genes, so that the ther-
apy would be more effective8. However, it is expected that
the development of flexible and firm modern approaches
for such integrated genome analyses would be essential
for continuous development of human genetics9. Recent
advances in understanding molecular aberrations that
make a foundation in melanoma oncogenesis are proba-
bly going to improve diagnosis, prognosis and treatment
of melanoma.
R E F E R E N C E S
1. CHIN L, Nat Cancer, 3 (2003) 559. — 2. SATYAMOORTHY K,
CHEHAB NH, WATERMAN MJ, LIEN MC, EL-DEIRY WS, HERLYN M,
HALAZONETIS TD, Cell Growth Differ, 11 (2000) 467. — 3. BATINAC T,
ZAMOLO G, RU@I] A, PER[I], Coll Antropol, 31 (2007) 23. — 4.
L. Lugovi} Mihi} et al.: Apoptosis in Malignant Melanoma, Coll. Antropol. 34 (2010) Suppl. 2: 303–306
305
WRONE ST, BERGSTORM J, QUEVEDO ME, REDDY V, GUTIERREZ-
-STEIL C, NICKOLOFF BJ. J Dermatol Sci, 19 (1999) 53. — 5. HAUPT S,
BERGER M, GOLDBERG Z, HAUPT Y, J Cell Sci, 116 (2003) 4077. — 6.
[ITUM M, BULJAN M, O@ANI]-BULI] S, [IMI] D, Coll Antropol, 31
(2007) 13. — 7. LARSON P, OLLINGER K, RODSAHL I, Br J Dermatol,
155 (2006) 292. — 8. ERB P, JI J, KUMP E, MIELGO A, WERNLI M, Adv
Exp Med Biol, 624 (2008) 283. — 9. SEKULI] A, HALUSKA P JR, MIL-
LER AJ, GENEBRIERA DE LAMO J, EJADI S, PULIDO JS, SALOMAO
DR, THORLAND EC, VILE RG, SWANSON DL, POCKAJ BA, LAMAN
SD, PITTELKOW MR, MARKOVIC SN, 83 (2008) 825. — 10. HAASS
NK, SMALLEY KS, LI L, Pigment Cell Res, 18 (2005) 150. — 11. CLARK
WH, ELDER DE, GUERRY DT, Hum Pathol, 15 (1984) 1147. — 12. RI-
GEL SD, FRIEDMAN RJ, DZUBOW LM, REINTGEN DS, CJYSTRYN B,
MARKS R, Cancer of the skin (Mosby-Elsevier, New Haven, 2005). — 13.
KAISER HE, BODEY B, SIEGEL SE, GROGER AM, BODERY B, In vivo,
14 (2000) 773. — 14. OMHOLT K, PLATZ A, KANTER L, Clin Cancer
Res, 9 (2003) 6483. — 15. ESKANDARPOUR M, KIAII S, ZHU C, Int J
Cancer, 115 (2005) 65. — 16. THOMPSON JF, SCOLYER RA, KEFFORD
RF, Lancet, 365 (2005) 687. — 17. BENNETT DC, Pigment Cell Mela-
noma Res, 21 (2008) 27. — 18. BATINAC T, HADZISEJDI] I, BRUMINI
G, RUZI] A, VOJNIKOVI] B, ZAMOLO G, Coll Antropol, 31 (2007) 17.
— 19. CORY S, ADAMS JM, Nat Rev Cancer, 2 (2002) 647. — 20. LEITER
U, SCHMID ADAMS JM, Nat Rev Cancer, 2 (2002) 647. — 21. DE
GRUIJL FR, Methods Enzymol, 319 (2000) 359. — 22. FU YC, JIN XP,
WIE SM, LIN HF, KACEW S, Toxicol Environ Health, 61 (2000) 177. —
23. PETITCLERC E, STROMBLAD S, SCHALSCHA TL, Cancer Res, 59
(1999) 2724. — 24. MILLER AJ, MIHM MC, N Engl J Med 355 (2006) 51.
— 25. BOON T, COULIE PG, EYNDE BJ, Annu Rev Immunol, 24 (2006)
175. — 26. FULDA S, DEBATIN KM, Oncogene, 25 (2006) 4798. — 27.
GLINSKY GV, GLINSKY VV, IVANOVA AB, HUESER CJ, Cancer Lett.
115 (1997) 185. — 28. VALENTE P, FASSINA G, MELCHIORI A, Int J
Cancer, 75 (1998) 246. — 29. GREEN DR, KROEMER G, Science, 305
(2004) 626. — 30. LUGOVI] L, [ITUM M, KOS L, Acta Dermatovenerol
Croat, 13 (2005) 36.
L. Lugovi} Mihi}
Department of Dermatology and Venereology, University Hospital »Sestre milosrdnice«, Vinogradska cesta 29,
10000 Zagreb, Croatia
e-mail: liborija@yahoo.com
ULOGA APOPTOZE U PATOGENEZI MALIGNOG MELANOMA
S A @ E T A K
Nastanak malignog melanoma je vrlo slo`en proces koji uklju~uje niz patogenetkih stani~nih doga|aja. U procesu
maligne promjene melanocita i njihove zlo}udne transformacije iz nevusa u melanom va`nu ulogu ima mutacija razli-
~itih gena te niz drugih stani~nih mehanizama. Apoptoza je aktivni, genetski kontroliran proces programirane stani~ne
smrti koja dovodi do destrukcije i smrti stanica bez uklju~ivanja okolnih stanica ili upalnog odgovora. Pritom se u
stanicama malignog melanoma odvijaju poreme}eni mehanizmi regulacije i apoptoze stanica, {to dovodi do njihovog
nekontroliranog umna`anja i rasta melanocita. Apoptoza je proces koji uklju~uje dva glavna puta, unutarnji i vanjski
apoptoti~ki put, koji se ispreple}u u pojedinim fazama te u kona~nici dovode do pojave apoptoze. Mo`e se re}i da mole-
kularni doga|aji koji reguliraju stani~no pre`ivljavanje, zastoj normalnog rasta, apoptozu i diferencijaciju stanica, do-
prinose ukupnoj patogenezi malignog rasta stanica. Smatra se da bi u budu}nosti upoznavanje molekularnih pore-
me}aja i stani~nih procesa, kao procesa stani~ne signalizacije, regulacije stani~nog ciklusa i stani~ne apoptoze, bilo
klju~no za bolje pra}enje bolesnika i racionalni plan za {to uspje{nije lije~enja.
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